Summary:
A phase 2, randomized, double-blind, double-blind, double-dummy, placebo and active-controlled, multicenter, parallel group study to evaluate the efficacy and safety of a new medication in patients with type 2 diabetes mellitus.
Qualified Participants Must:
• Be between 18 and 70 years of age
•
Be diagnosed with Type 2 Diabetes
•
Be either drug-naive OR be treated with Metformin only
Qualified Participants May Receive:
- All study-related visits, exams,and lab work provided free of charge.
- Glucose testing meter and all testing supplies.
- Compensation for time and travel may be provided.